Chair
Member
Audit Committee Position

Jon Kuwahara

Mr. Kuwahara previously served as a director of Emmaus and as Chairman of the Audit Committee and a member of the Corporate Governance and Compensation Committees of the Board from January 2016 to September 2018. He has served as Vice President – Finance of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), San Diego, California, since August 2021. Prior to that time, Mr. Kuwahara served as Senior Vice President – Finance and Administration of Novus Therapeutics, Inc. (NASDAQ: NVUS), Irvine, California, from July 2016 to July 2021 and in senior finance and accounting positions with a number of other life sciences companies. Mr. Kuwahara is a Certified Public Accountant and holds a Bachelor of Business Administration, Accounting, degree from the University of Hawaii at Manoa, Honolulu, Hawaii.

Chair

Ian Zwicker

Ian Zwicker was appointed as a director on October 4, 2022. He previously served as a director, Chair of the Compensation Committee and member of the Governance and Nominations Committee of our Board of Directors from the completion of our merger transaction with EMI Holding, Inc. on July 17, 2019, until his retirement as a director in conjunction with our Annual Meeting of Stockholders held on November 23, 2021. He had served as a director of EMI Holding, Inc. since December 7, 2015. Mr. Zwicker is the founder of Zwicker Advisory Group, an independent financial advisory consulting firm, and has been its Chief Executive Officer since 2014. From 1981 to 1990, Mr. Zwicker served as Managing Director and held a variety of management positions at the investment banking firms of SG Cowen and Hambrecht & Quist. From 1990 to 1999, Mr. Zwicker served as Managing Director and head of worldwide technology investment banking for Donaldson, Lufkin & Jenrette Securities Corporation, and from 2000 to 2001 as the President of WR Hambrecht + Co (WRH). He was a Director of Stirling Energy Systems, Inc. from 2006 to 2012. Mr. Zwicker was a Partner at WRH and was also Head of Capital Markets from 2013 to 2014. We believe Mr. Zwicker is qualified to serve as a director due to his prior service on the Board of Directors and standing Board committees and his extensive investment banking and financial expertise and experience.

Member

Audit Committee Charter

Download
Governance and Nominations Committee Position

Robert Dickey IV, MBA*

Robert Dickey IV has experience as a CFO as well as in other C-level and Board positions in life sciences and medical device companies, both private and publicly-traded, across all stages of development. Before that, he was an investment banker, mostly at Lehman Brothers. He is currently a Managing Director at Foresite Advisors since March 2020 and was previously a Managing Director at Danforth Advisors from August 2018 to March 2020. Foresite Advisors provides finance support and strategy for life science companies, including strategic CFO advisory, financial analysis, capital raising, and transactional support/execution for public offerings and M&A. Mr. Dickey serves as a member of the board of directors at AngioGenex and served as a board member at Sanuthera, Inc., a privately held medical device company. Previously, he was CFO at Motif Bio PLC, a dual-listed, advanced stage antibiotics company. Mr. Dickey’s prior operating experience includes CFO at Tyme Technologies; CFO at NeoStem (now Caladrius Biosciences); SVP at Hemispherx; CFO and Business Unit Manager at StemCyte; and CEO and COO at Protarga. Mr. Dickey holds an M.B.A. from The Wharton School, University of Pennsylvania, and an A.B. from Princeton University.

Member

Wei Peu (Derek) Zen, MBA

Mr. Zen is Vice Chairman and Chief Executive Officer of Wai Kee Holdings Limited., a Hong Kong-based construction and infrastructure company whose shares are listed on the Main Board of the Hong Kong Stock Exchange Limited. He is also the Chairman of Build King Holdings Limited and Chairman of Road King Infrastructure Limited, both of which are subsidiaries of Wai Kee Holdings Limited. Mr. Zen has over 45 years of experience in civil engineering, and is responsible for the overall management of the Wai Kee Holdings Limited group of companies and oversees the operations of the group’s construction, quarry and concrete divisions. Mr. Zen holds a B.Sc. degree in Engineering from The University of Hong Kong and a M.B.A. degree from The Chinese University of Hong Kong and is a member of both the Institution of Civil Engineers and fellow member of the Hong Kong Institution of Engineers and the Institute of Quarrying, UK respectively. He is a past Honorary Treasurer of Hong Kong Construction Association and a member of HKTDC Infrastructure Development Advisory Committee. He is also the President of Hong Kong Contract Bridge Association. 

Member

Governance and Nominations Committee Charter

Download
Compensation Committee Position

Robert Dickey IV, MBA*

Robert Dickey IV has experience as a CFO as well as in other C-level and Board positions in life sciences and medical device companies, both private and publicly-traded, across all stages of development. Before that, he was an investment banker, mostly at Lehman Brothers. He is currently a Managing Director at Foresite Advisors since March 2020 and was previously a Managing Director at Danforth Advisors from August 2018 to March 2020. Foresite Advisors provides finance support and strategy for life science companies, including strategic CFO advisory, financial analysis, capital raising, and transactional support/execution for public offerings and M&A. Mr. Dickey serves as a member of the board of directors at AngioGenex and served as a board member at Sanuthera, Inc., a privately held medical device company. Previously, he was CFO at Motif Bio PLC, a dual-listed, advanced stage antibiotics company. Mr. Dickey’s prior operating experience includes CFO at Tyme Technologies; CFO at NeoStem (now Caladrius Biosciences); SVP at Hemispherx; CFO and Business Unit Manager at StemCyte; and CEO and COO at Protarga. Mr. Dickey holds an M.B.A. from The Wharton School, University of Pennsylvania, and an A.B. from Princeton University.

Member

Compensation Committee Charter

Download

*Financial Expert

Jon Kuwahara

Mr. Kuwahara previously served as a director of Emmaus and as Chairman of the Audit Committee and a member of the Corporate Governance and Compensation Committees of the Board from January 2016 to September 2018. He has served as Vice President – Finance of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), San Diego, California, since August 2021. Prior to that time, Mr. Kuwahara served as Senior Vice President – Finance and Administration of Novus Therapeutics, Inc. (NASDAQ: NVUS), Irvine, California, from July 2016 to July 2021 and in senior finance and accounting positions with a number of other life sciences companies. Mr. Kuwahara is a Certified Public Accountant and holds a Bachelor of Business Administration, Accounting, degree from the University of Hawaii at Manoa, Honolulu, Hawaii.

Ian Zwicker

Ian Zwicker was appointed as a director on October 4, 2022. He previously served as a director, Chair of the Compensation Committee and member of the Governance and Nominations Committee of our Board of Directors from the completion of our merger transaction with EMI Holding, Inc. on July 17, 2019, until his retirement as a director in conjunction with our Annual Meeting of Stockholders held on November 23, 2021. He had served as a director of EMI Holding, Inc. since December 7, 2015. Mr. Zwicker is the founder of Zwicker Advisory Group, an independent financial advisory consulting firm, and has been its Chief Executive Officer since 2014. From 1981 to 1990, Mr. Zwicker served as Managing Director and held a variety of management positions at the investment banking firms of SG Cowen and Hambrecht & Quist. From 1990 to 1999, Mr. Zwicker served as Managing Director and head of worldwide technology investment banking for Donaldson, Lufkin & Jenrette Securities Corporation, and from 2000 to 2001 as the President of WR Hambrecht + Co (WRH). He was a Director of Stirling Energy Systems, Inc. from 2006 to 2012. Mr. Zwicker was a Partner at WRH and was also Head of Capital Markets from 2013 to 2014. We believe Mr. Zwicker is qualified to serve as a director due to his prior service on the Board of Directors and standing Board committees and his extensive investment banking and financial expertise and experience.

Robert Dickey IV, MBA

Robert Dickey IV has experience as a CFO as well as in other C-level and Board positions in life sciences and medical device companies, both private and publicly-traded, across all stages of development. Before that, he was an investment banker, mostly at Lehman Brothers. He is currently a Managing Director at Foresite Advisors since March 2020 and was previously a Managing Director at Danforth Advisors from August 2018 to March 2020. Foresite Advisors provides finance support and strategy for life science companies, including strategic CFO advisory, financial analysis, capital raising, and transactional support/execution for public offerings and M&A. Mr. Dickey serves as a member of the board of directors at AngioGenex and served as a board member at Sanuthera, Inc., a privately held medical device company. Previously, he was CFO at Motif Bio PLC, a dual-listed, advanced stage antibiotics company. Mr. Dickey’s prior operating experience includes CFO at Tyme Technologies; CFO at NeoStem (now Caladrius Biosciences); SVP at Hemispherx; CFO and Business Unit Manager at StemCyte; and CEO and COO at Protarga. Mr. Dickey holds an M.B.A. from The Wharton School, University of Pennsylvania, and an A.B. from Princeton University.

Wei Peu (Derek) Zen, MBA

Mr. Zen is Vice Chairman and Chief Executive Officer of Wai Kee Holdings Limited., a Hong Kong-based construction and infrastructure company whose shares are listed on the Main Board of the Hong Kong Stock Exchange Limited. He is also the Chairman of Build King Holdings Limited and Chairman of Road King Infrastructure Limited, both of which are subsidiaries of Wai Kee Holdings Limited. Mr. Zen has over 45 years of experience in civil engineering, and is responsible for the overall management of the Wai Kee Holdings Limited group of companies and oversees the operations of the group’s construction, quarry and concrete divisions. Mr. Zen holds a B.Sc. degree in Engineering from The University of Hong Kong and a M.B.A. degree from The Chinese University of Hong Kong and is a member of both the Institution of Civil Engineers and fellow member of the Hong Kong Institution of Engineers and the Institute of Quarrying, UK respectively. He is a past Honorary Treasurer of Hong Kong Construction Association and a member of HKTDC Infrastructure Development Advisory Committee. He is also the President of Hong Kong Contract Bridge Association. 

Robert Dickey IV, MBA

Robert Dickey IV has experience as a CFO as well as in other C-level and Board positions in life sciences and medical device companies, both private and publicly-traded, across all stages of development. Before that, he was an investment banker, mostly at Lehman Brothers. He is currently a Managing Director at Foresite Advisors since March 2020 and was previously a Managing Director at Danforth Advisors from August 2018 to March 2020. Foresite Advisors provides finance support and strategy for life science companies, including strategic CFO advisory, financial analysis, capital raising, and transactional support/execution for public offerings and M&A. Mr. Dickey serves as a member of the board of directors at AngioGenex and served as a board member at Sanuthera, Inc., a privately held medical device company. Previously, he was CFO at Motif Bio PLC, a dual-listed, advanced stage antibiotics company. Mr. Dickey’s prior operating experience includes CFO at Tyme Technologies; CFO at NeoStem (now Caladrius Biosciences); SVP at Hemispherx; CFO and Business Unit Manager at StemCyte; and CEO and COO at Protarga. Mr. Dickey holds an M.B.A. from The Wharton School, University of Pennsylvania, and an A.B. from Princeton University.